Literature DB >> 17015702

The cyclin-dependent kinase inhibitor p27kip1 is required for transplantation tolerance induced by costimulatory blockade.

Emily A Rowell1, Liqing Wang, Wayne W Hancock, Andrew D Wells.   

Abstract

The cyclin-dependent kinase (CDK) inhibitor p27kip1 is an important negative regulator of the cell cycle that sets a threshold for mitogenic signals in T lymphocytes, and is required for T cell anergy in vitro. To determine whether p27(kip1) is required for tolerance in vivo, we performed cardiac allograft transplantation under conditions of combined CD28/CD40L costimulatory blockade. Although this treatment induced long-term allograft survival in wild-type recipients, costimulatory blockade was no longer sufficient to induce tolerance in mice lacking p27kip1. Rejected allografts from p27kip1-/- mice contained more CD4+ T lymphocytes and exhibited more tissue damage than allografts from tolerant, wild-type mice. Infiltrating p27kip1-deficient T cells, but not wild-type T cells, exhibited nuclear expression of cyclins E and A, indicating uncontrolled T cell cycle progression in the graft. The failure of tolerance in p27kip1-/- mice was also accompanied by markedly increased numbers of allospecific, IFN-gamma-producing cells in the periphery, and occurred despite apparently normal regulatory T cell activity. These data demonstrate that the CDK inhibitor p27kip1 enforces the costimulatory requirement for the expansion and differentiation of alloimmune effector T lymphocytes in vivo, and point to CDKs as novel targets for immunosuppressive or tolerance-inducing therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17015702     DOI: 10.4049/jimmunol.177.8.5169

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

Review 1.  Molecular mechanisms for adaptive tolerance and other T cell anergy models.

Authors:  Seeyoung Choi; Ronald H Schwartz
Journal:  Semin Immunol       Date:  2007-04-02       Impact factor: 11.130

Review 2.  Cyclin-dependent kinases: molecular switches controlling anergy and potential therapeutic targets for tolerance.

Authors:  Andrew D Wells
Journal:  Semin Immunol       Date:  2007-03-23       Impact factor: 11.130

3.  The cyclin dependent kinase inhibitor (R)-roscovitine mediates selective suppression of alloreactive human T cells but preserves pathogen-specific and leukemia-specific effectors.

Authors:  Anoma Nellore; Bianling Liu; Nikolaos Patsoukis; Vassiliki A Boussiotis; Lequn Li
Journal:  Clin Immunol       Date:  2014-03-12       Impact factor: 3.969

Review 4.  New roles for cyclin-dependent kinases in T cell biology: linking cell division and differentiation.

Authors:  Andrew D Wells; Peter A Morawski
Journal:  Nat Rev Immunol       Date:  2014-03-07       Impact factor: 53.106

Review 5.  Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family.

Authors:  Hélène Bour-Jordan; Jonathan H Esensten; Marc Martinez-Llordella; Cristina Penaranda; Melanie Stumpf; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

6.  Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation.

Authors:  Nikolaos Patsoukis; Julia Brown; Victoria Petkova; Fang Liu; Lequn Li; Vassiliki A Boussiotis
Journal:  Sci Signal       Date:  2012-06-26       Impact factor: 8.192

7.  HelicoVax: epitope-based therapeutic Helicobacter pylori vaccination in a mouse model.

Authors:  Steven F Moss; Leonard Moise; Dong Soo Lee; Woojin Kim; Songhua Zhang; Jinhee Lee; Arlin B Rogers; William Martin; Anne S De Groot
Journal:  Vaccine       Date:  2011-01-12       Impact factor: 3.641

8.  Regulation of alloimmune Th1 responses by the cyclin-dependent kinase inhibitor p21 following transplantation.

Authors:  Theodore H Welling; Guanyi Lu; Keri Csencsits; Sherri C Wood; Lamis Jarvinen; D Keith Bishop
Journal:  Surgery       Date:  2007-12-21       Impact factor: 3.982

Review 9.  Immune tolerance and transplantation.

Authors:  Onder Alpdogan; Marcel R M van den Brink
Journal:  Semin Oncol       Date:  2012-12       Impact factor: 4.929

10.  Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression.

Authors:  Dewan Md Sakib Hossain; Sarah Javaid; Mingmei Cai; Chunsheng Zhang; Anandi Sawant; Marlene Hinton; Manjiri Sathe; Jeff Grein; Wendy Blumenschein; Elaine M Pinheiro; Alissa Chackerian
Journal:  J Clin Invest       Date:  2018-01-16       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.